GSK701

GSK701

Translational
-
Human volunteers
GSK
Asexual blood stages
Uncomplicated malaria treatments and resistance management (TPP-1)
Product vision
  • Uncomplicated malaria treatment and resistance management
MOA
  • Inhibition of Plasmodium falciparum Acyl-CoA synthetase 10/11
Key features
  • Novel mode of action and structure
  • Highly potent and active against resistant strains
  • Fast killing in vitro and in vivo
  • Low single dose prediction
Challenges
  • Low potency on P. vivax and P. knowlesi malaria
  • Limited solubility of crystalline material
Status
  • First-in-human study completed, induced blood-stage malaria study protocol submitted
Next milestone
  • Complete phase I programme (including volunteer infection study)
  • Identification of combination partner
Previously
  • Discovery by GSK with support from the Wellcome Trust
  • Full reference name is MMV1582367
Project Director
  • Dr Benoît Bestgen